{"nctId":"NCT00927862","briefTitle":"Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin","startDateStruct":{"date":"2008-08"},"conditions":["Thromboembolism"],"count":2415,"armGroups":[{"label":"Standard IWPC warfarin dosing algorithm","type":"ACTIVE_COMPARATOR","interventionNames":["Genetic: IWPC adapted genotype-guided dosing algorithm for warfarin"]},{"label":"Modified IWPC warfarin dosing algorithm","type":"EXPERIMENTAL","interventionNames":["Genetic: Modified IWPC genetic-guided warfarin dosing algorithm"]},{"label":"Historical controls","type":"OTHER","interventionNames":["Other: Standard of care treatment"]}],"interventions":[{"name":"IWPC adapted genotype-guided dosing algorithm for warfarin","otherNames":["IWPC=international warfarin pharmacogenetic collaboration"]},{"name":"Modified IWPC genetic-guided warfarin dosing algorithm","otherNames":["IWPC=international warfarin pharmacogenetic collaboration"]},{"name":"Standard of care treatment","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* New participants will be those \\>=18 years old who are appropriate candidates for and being initiated on warfarin therapy with target international normalized prothrombin time ratio (INR) range of either 2-3 or 2.5-3.5 and with intent to be treated for at least 1 month and willing to sign informed consent.\n* Those with target INR 2.5-3.5 may be enrolled with dose adjustment for this higher target per Gage et-al. (i.e., 11% increase in dose).\n* Dose modification also will be made for amiodarone based on prior, published experience (i.e., 22% decrease in dose).\n\nExclusion Criteria:\n\n* Those not appropriate for warfarin (e.g., pregnancy) or for pharmacogenetic (PG)-guided dosing for any reason,\n* Those having received rifampin within 3 weeks,\n* Those with severe co-morbidities (e.g., creatinine \\> 2.5,hepatic insufficiency, active malignancy, advanced physiological age, noncompliance risk, expected survival \\<6 months), and\n* Physician or patient preference.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percent of Out of Range (OOR) International Normalized Prothrombin Time Ratio (INRs) in the Standard and Modified Pharmacogenetic Arms.","description":"The percent of out of range (OOR) international normalized prothrombin time ratio (INRs) in the standard and modified pharmacogentic algorithms at 1 month. To account for laboratory INR-measurement error, a 10% margin outside of the target range was allowed in determination of OOR values, ie, INRs \\<1.8, \\>3.3 for INR 2.5 target; \\<2.25, \\>3.85 for INR 3.0 target. What is reported is the percent of patients with an OOR INR at 1 month.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","spread":null},{"groupId":"OG001","value":"31.8","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percent of INRs ≥4 or ≤1.5 for the Modified IWPC Warfarin Algorithm and the Standard IWPC Warfarin Algorithm","description":"The percent of INRs ≥4 or ≤1.5 for the pharmacogenetic (modified IWPC warfarin algorithm and the standard IWPC warfarin) algorithms. What is reported is the percent of patients with INRs ≥4 or ≤1.5 at the end of follow-up.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":"20.5"},{"groupId":"OG001","value":"15.4","spread":"18.2"}]}]}]},{"type":"SECONDARY","title":"The Percent of INRs ≥4 or ≤1.5 or SAEs Among the Modified IWPC Warfarin Algorithm and Standard IWPC Warfarin Algorithm.","description":"What is reported is the percent of patients with INRs ≥4 or ≤1.5 or having experienced a serious adverse event (SAE) at the end of follow-up.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.6","spread":null},{"groupId":"OG001","value":"59.2","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of INRs Measured up to 3 Months in the Pharmacogenetic (PG) (Modified and Standard) Algorithms and Parallel Controls.","description":"What is reported is the mean number of INRs measured/drawn among the patients in each arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.70","spread":"3.99"},{"groupId":"OG001","value":"7.47","spread":"7.27"}]}]}]},{"type":"SECONDARY","title":"Prediction of a Stable Maintenance Dose Among the Pharmacogenetic (PG)-Guided Dosing Algorithms and the Parallel Controls","description":"Prediction of a stable maintenance dose (within 1 mg/day) among the pharmacogenetic (PG)-guided dosing and the parallel control group. For the parallel control group, an empiric starting dose of 5 mg/day was assumed. What is reported is the percent of patients who had their maintenance dose predicted as described above.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.2","spread":null},{"groupId":"OG001","value":"37.6","spread":null}]}]}]},{"type":"PRIMARY","title":"The Percent of Out of Range (OOR) INRs in Pharmacogenetic-guided Patients and Parallel Controls","description":"The percent of out of range (OOR) INRs in the pharmacogenetic (PG)-dosing (standard + modified IWPC warfarin algorithms) and parallel controls. A 10% margin outside of the target INR range was allowed in determination of OOR values, ie, INRs \\<1.8, \\>3.3 for INR 2.5 target; \\<2.25, \\>3.85 for INR 3.0 target. What is reported is the percent of patients with OOR INRs at 1 month.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.2","spread":null},{"groupId":"OG001","value":"41.5","spread":null}]}]}]},{"type":"PRIMARY","title":"The Percent of Time in Therapeutic Range (TTR) for the Standard and Modified Pharmacogenetic Algorithms.","description":"The percent of time in therapeutic INR range for the standard and modified pharmacogenetic algorithms at 1 month. To account for laboratory INR-measurement error, a 10% margin inside of the target range was allowed in determine TTR values, ie, INRs 1.8-3.3 for INR 2.5 target; 2.25-3.85 for INR 3.0 target. What is reported is the percent of TTR for each patient during 1 month.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.2","spread":null},{"groupId":"OG001","value":"67.5","spread":null}]}]}]},{"type":"PRIMARY","title":"The Time in Therapeutic Range (TTR) for the Pharmacogenetic-guided Patients and Parallel Controls","description":"The percent of time in therapeutic INR range for the pharmacogenetic (PG)-dosing (standard + modified IWPC warfarin algorithms) guided patients and parallel controls. To account for laboratory INR-measurement error, a 10% margin inside of the target range was allowed in determine TTR values, ie, INRs 1.8-3.3 for INR 2.5 target; 2.25-3.85 for INR 3.0 target. What is reported is the percent of TTR for each patient during 1 month.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.9","spread":null},{"groupId":"OG001","value":"58.4","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percent of INRs ≥4 or ≤1.5 in the Pharmacogenetic (PG)-Guided Dosing Arms and the Parallel Control Arm","description":"What is reported is the percent of patients with an INR ≥4 or ≤1.5 at the end of follow-up.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":"19.4"},{"groupId":"OG001","value":"27.4","spread":"32.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":22,"n":487},"commonTop":["INR >=4 or <=1.5"]}}}